High dose cytosine arabinoside in the treatment of adult acute myelogenous leukaemia
Nemet, D.; Labar, B.; Bogdanić, V.; Hauptman, E.; Jaksić, B.; Minigo, H.; Sertić, D.; Mrsić, M.; Pavletić, Z.; Kovacević, J.
Bone Marrow Transplantation 4(Suppl 3): 42-44
1989
ISSN/ISBN: 0268-3369 PMID: 2697399 Document Number: 336359
Document emailed within 1 workday
Related Documents
Ghaddar, H.M.; Plunkett, W.; Kantarjian, H.M.; Pierce, S.; Freireich, E.J.; Keating, M.J.; Estey, E.H. 1994: Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside Leukemia 8(8): 1269-1274Wysocki, M.; Nowaczyk-Michalak, A.; Pilecki, O.; Trybuś, L.; Balcar-Boroń, A. 1992: Jaundice following high--dose arabinoside cytosine in a child with acute myelogenous leukemia Acta Haematologica Polonica 23(3): 197-199
Takemoto, Y.; Sampi, K.; Kuraishi, Y.; Okabe, K.; Tamura, K.; Mizoguchi, H.; Saito, H.; Masaoka, T.; Ogawa, M. 1999: A prospective randomized trial of KRN8602 and cytosine arabinoside vs. daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. the KRN8602 Leukemia Study Group International Journal of Hematology 70(1): 20-25
Taguchi, H.; Kubonishi, I.; Takehara, N.; Uemura, Y.; Iwahara, Y.; Eguchi, T.; Miyagi, T.; Sugito, S.; Muneishi, H.; Tanaka, Y. 1992: Intensive induction chemotherapy of adult acute myelogenous leukemia by continuing daunorubicin, behenoyl-cytosine arabinoside, 6-mercaptopurine and prednisolone until marrow aplasia Gan to Kagaku Ryoho. Cancer and ChemoTherapy 19(9): 1309-1314
Sanz, M.A.; Martínez, J.; Borrego, D.; Martín-Aragonés, G.; Lorenzo, I.; Sanz, G.; Sayas, M.J.; Jarque, I.; Pastor, E.; Rafecas, J. 1987: High-dose cytosine arabinoside and mitoxantrone in high-risk acute nonlymphoblastic leukemia Seminars in Oncology 14(2 Suppl 1): 18-20
Ohshima, A.; Yoshida, K.; Sato, T.; Miyazaki, S.; Yanagisawa, M.; Nakayama, Y.; Takahashi, T.; Mamiya, S.; Fukusima, Y.; Miura, A.B. 1987: Intermediate- and high-dose cytosine arabinoside therapy in acute refractory leukemia Gan to Kagaku Ryoho. Cancer and ChemoTherapy 14(1): 192-195
Klener, P.; Háber, J. 1985: Treatment of refractory leukemia with high-dose cytosine arabinoside Neoplasma 32(1): 113-117
Guilhot, F. 1993: Interferon alfa and low-dose cytosine-arabinoside for the treatment of patients with chronic myelogenous leukemia in chronic phase. French CML Study Group Seminars in Hematology 30(3 Suppl 3: 24-25
Hoelzer, D.; Thiel, E.; Löffler, H.; Büchner, T.; Ganser, A.; Heil, G.; Kurrle, E.; Heimpel, H.; Koch, P.; Lipp, T. 1987: Teniposide (VM-26) and cytosine arabinoside as consolidation therapy in adult high-risk patients with acute lymphoblastic leukemia Seminars in Oncology 14(2 Suppl 1: 92-97
Herzig, R.H.; Coccia, P.F.; Lazarus, H.M.; Strandjord, S.E.; Graham-Pole, J.; Cheung, N.K.; Gordon, E.M.; Gross, S.; Spitzer, T.R.; Warkentin, P.I. 1985: Bone marrow transplantation for acute leukemia and lymphoma with high-dose cytosine arabinoside and total body irradiation Seminars in Oncology 12(2 Suppl 3: 184-186
Johnson, N.T.; Crawford, S.W.; Sargur, M. 1987: Acute acquired demyelinating polyneuropathy with respiratory failure following high-dose systemic cytosine arabinoside and marrow transplantation Bone Marrow Transplantation 2(2): 203-207
Pedersen, G.; Stentoft, J.; Pedersen, J.O.; Jensen, M.K. 1994: Treatment of acute myeloid leukemia in the elderly with low-dose cytosine arabinoside Ugeskrift for Laeger 156(43): 6380-6384
Gingrich, R.D.; Armitage, J.O.; Burns, C.P. 1978: Treatment of adult acute lymphoblastic leukemia with cytosine arabinoside, vincristine, and prednisone Cancer Treatment Reports 62(9): 1389-1391
Kobayashi, S.; Sakai, H.; Tomiazwa, T.; Koiso, H.; Kim, K.; Ueki, K.; Tamura, J.; Yano, S.; Naruse, T.; Karasawa, M. 1999: Successful low-dose cytosine arabinoside treatment in a patient with acute leukemia from idiopathic myelofibrosis Journal of Medicine 30(1-2): 101-109
Huang, M.E.; Ye, Y.C.; Zhao, L. 1987: Treatment of acute promyelocytic leukemia by retinoic acid with or without low dose cytosine arabinoside: report of 4 cases Zhonghua Nei Ke Za Zhi 26(6): 330
Vogler, W.R.; Velez-Garcia, E.; Omura, G.; Raney, M. 1989: A phase-three trial comparing daunorubicin or idarubicin combined with cytosine arabinoside in acute myelogenous leukemia Seminars in Oncology 16(1 Suppl 2: 21-24
Harakati, M.S. 1999: Cytosine arabinoside, mitoxantrone, and etoposide in the treatment of adult patients with previously untreated acute myeloid leukemia Saudi Medical Journal 20(4): 291-295
Hines, J.D.; Mazza, J.J.; Oken, M.M.; Bennett, J.M.; Adelstein, D.J.; Keller, A.; O'Connell, M.J. 1985: High-dose cytosine arabinoside and mAMSA induction and consolidation in patients with previously untreated de novo acute nonlymphocytic leukemia: Phase i Pilot Study for the Eastern Cooperative Oncology Group Seminars in Oncology 12(2 Suppl 3: 117-119
Herzig, R.H.; Herzig, G.P.; Wolff, S.N.; Hines, J.D.; Fay, J.W.; Phillips, G.L. 1987: Central nervous system effects of high-dose cytosine arabinoside Seminars in Oncology 14(2 Suppl 1: 21-24
Keating, M.J.; Estey, E.; Plunkett, W.; Iacoboni, S.; Walters, R.; Kantarjian, H.; Andersson, B.; Beran, M.; McCredie, K.B.; Freireich, E.J. 1985: Evolution of clinical studies with high-dose cytosine arabinoside at the M.D. Anderson Hospital Seminars in Oncology 12(2 Suppl. 3): 98-104